Highlights Newsletter 3 This newsletter presents you the following key sessions: Watch the video interview with Geertjan van Tienhoven, MD, about preliminary results of the phase III PREOPANC-1 trial: preoperative chemoradiotherapy versus upfront surgery in patients with resectable and borderline resectable pancreatic cancer Nivolumab plus chemotherapy as first-line therapy showed improved progression-free survival compared to chemotherapy in NSCLC patients with <1% PD-L1 expression Most women with early-stage breast cancer can forgo chemotherapy when treatment is guided by the Oncotype DX 21-gene assay No survival benefit of adding hyperthermic intraperitoneal chemotherapy to surgery in patients with colorectal peritoneal carcinomatosis Sustained benefit of nivolumab over ipilimumab in the adjuvant treatment of resected stage III or IV melanoma with a high risk of recurrence